DOCSLIB.ORG

Effects of Dehydroepiandrosterone on Cognition: an Electrophysiological Approach

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Universidade de Lisboa Faculdade de Medicina de Lisboa Effects of Dehydroepiandrosterone on Cognition: an Electrophysiological Approach Sónia Isabel do Vale Fernandes Orientadores: Professor Doutor João Maria Martin Martins Professor Doutor Carles Enric Escera Micó Doctoral Program in Metabolic Disorders and Eating Behavior Tese especialmente elaborada para obtenção do grau de Doutor em Medicina, Especialidade Endocrinologia 2016 Universidade de Lisboa Faculdade de Medicina de Lisboa Effects of Dehydroepiandrosterone on Cognition: an Electrophysiological Approach Sónia Isabel do Vale Fernandes Orientadores: Professor Doutor João Maria Martin Martins Professor Doutor Carles Enric Escera Micó Doctoral Program in Metabolic Disorders and Eating Behavior Tese especialmente elaborada para obtenção do grau de Doutor em Medicina, Especialidade Endocrinologia Júri: Presidente: Doutor José Luís Bliebernicht Ducla Soares, Professor Catedrático em regime de tenure e Vice-Presidente do Conselho Científico da Faculdade de Medicina da Universidade de Lisboa (por subdelegação do Doutor José Augusto Gamito Melo Cristino, Professor Catedrático e Presidente do Conselho Científico da Faculdade de Medicina da Universidade de Lisboa) Vogais: - Professor Carles Enric Escera Micó, Full Professor (Catedràtic d´Universitat) da University of Barcelona; (co-Orientador) - Doutora Maria Helena Cardoso Pereira da Silva, Professora Associada Convidada do Instituto de Ciências Biomédicas Abel Salazar da Universidade do Porto; - Doutor Valeriano Alberto Pais Horta Leite, Professor Auxiliar Convidado da Faculdade de Ciências Médicas da Universidade Nova de Lisboa; - Doutor Rui Manuel Martins Victorino, Professor Catedrático da Faculdade de Medicina da Universidade de Lisboa; - Doutor Manuel Diamantino Pires Bicho, Professor Catedrático da Faculdade de Medicina da Universidade de Lisboa; - Doutor Manuel Augusto de Castro Pereira Barbosa, Professor Associado com Agregação da Faculdade de Medicina da Universidade de Lisboa; - Doutor João Maria Martin Martins, Professor Auxiliar Convidado da Faculdade de Medicina da Universidade de Lisboa; (Orientador). This work has been supported by the Spanish Ministry of Economy and Knowledge (CDS2007-00012), the Catalan Government (SGR2009-11 and SGR2014-177), ICREA (Catalan Institution for Research and Advanced Studies) Academia Distinguished Professorship awarded to Carles Escera, the Portuguese Calouste Gulbenkian Foundation (116503, 2011), Lisbon Medical School (Metabolic Disorders and Eating Behavior course and Endocrinology University Clinic), Hospital Association of Endocrinology and Diabetes (HEID) and Merck SA. 2016 As opiniões expressas nesta publicação são da exclusiva responsabilidade do seu autor. A impressão desta dissertação foi aprovada em Conselho Científico da Faculdade de Medicina de Lisboa em reunião de 19 de Abril de 2016. Dissertação apresentada à Faculdade de Medicina de Lisboa para obtenção do grau de Doutor em Medicina À minha família: aos que sucedo, aos que precedo e em especial ao meu marido. Liberdade Aqui nesta praia onde Não há nenhum vestígio de impureza, Aqui onde há somente Ondas tombando ininterruptamente, Puro espaço e lúcida unidade, Aqui o tempo apaixonadamente Encontra a própria liberdade. Sophia de Mello Breyner Andresen, in “Mar” “We know accurately only when we know little; doubt grows with knowledge.” Johann Wolfgang von Goethe Acknowledgements To Professor João Martin Martins for everything he taught me in endocrinology, for showing me the beauty of behavioral endocrinology, for teaching and letting me participate in his research, for the liberty and incentive to pursue the present research, for the active participation in the initial steps of this research and for the supervision of this thesis. To Professor Carles Escera, who kindly received me at the laboratory and the team he leads, allowing the present research. His outstanding expertise in electrophysiology and psychophysiology were fundamental for the present work. I also thank his invaluable help, support and friendly words along these years. To Lenka Selinger, whose work and friendship were fundamental. She actively participated in the research performed in Barcelona, taught me many practical aspects regarding electrophysiology research and shared some of my headaches while trying to solve research problems. To Professor Isabel do Carmo, for challenging me to pursue this doctoral program and for the positive and supportive attitude during its performance. To Professor Manuel Bicho, who kindly allowed me the use of the Genetics’ laboratory for the performance of the endocrine measurements and kindly followed the development of the present works and thesis. To Professor Rui Victorino, for his vote of confidence and supportive attitude. To Professor Manuel Barbosa for his support, friendship and incentive words. To Dr. Anabela Oliveira, the head of my emergency room team, for understanding and allowing my absence from that work while in Barcelona and for the positive attitude towards the professional development of the team elements. To Dr. Nelson de Melo, for the English corrections and his good will and friendship at all times. To José Valenzuela who programmed the computer sequences used in the experimental protocols and Francisco Diaz, who solved other informatics issues. To the other colleagues at the Barcelona Brainlab, namely to Irene Romero, who made me feel at home while abroad. To the study participants. To the unnamed ones who somehow contributed to the present works. To my friends and good colleagues. And Especially, to my lovely family, that really allowed my everyday work and happiness, without whom this thesis would not be possible. This work has been carried out in the Endocrinology University Clinic, led by Professor João Martin Martins and in the Genetics Laboratory, led by Professor Manuel Bicho, at the Lisbon Medical School, University of Lisbon (Lisbon, Portugal); in Santa Maria University Hospital (Lisbon, Portugal) led by Professor Isabel do Carmo; in the Institute for Brain, Cognition and Behavior (IR3C) and the Cognitive Neuroscience Research Group (Centre of Excellence established by the Generalitat de Catalunya) at the Department of Psychiatry and Clinical Psychobiology, Faculty of Psychology, University of Barcelona (Barcelona, Catalonia, Spain), led by Professor Carles Escera. Index Summary ....................................................................................................................... i Resumo ........................................................................................................................ v List of Original Publications in Relation to the Present Thesis ........................................ xi Abbreviations ............................................................................................................. xiii Introduction/Literature Review: Dehydroepiandrosterone and Dehydroepiandrosterone-sulphate as Neuroactive Steroids .......................................... 1 Synthesis and distribution ................................................................................................. 3 Changes along the life span and regulation .................................................................... 20 Mechanisms of action and cellular effects ...................................................................... 29 Cognitive and neuropsychiatric effects ........................................................................... 44 Electrophysiological and neuroimaging correlates ......................................................... 56 Aims and Hypothesis .................................................................................................. 83 Study I ........................................................................................................................ 87 Study II ...................................................................................................................... 107 Study III ..................................................................................................................... 141 Study IV .................................................................................................................... 173 Discussion ................................................................................................................. 205 Conclusions ............................................................................................................... 233 Future research and clinical perspectives ................................................................... 235 References ................................................................................................................ 237 Annex: Published articles included in the Thesis ........................................................ 299 Figure index Figure 1: Cyclopentanoperhydrophenanthrene structure, dehydroepiandrosterone and dehydroepiandrosterone-sulphate chemical structure. ....................................................... 3 Figure 2: Biochemical pathway for DHEA synthesis.. ............................................................ 5 Figure 3: Adrenal steroidogenesis.. ....................................................................................... 5 Figure 4: Steroidogenic pathway in the ovary.. .................................................................... 6 Figure 5: Steroidogenesis in human testis. ..........................................................................
Recommended publications
  • Dextromethorphan Attenuates Sensorineural Hearing Loss in an Animal Model and Population-Based Cohort Study

    Dextromethorphan Attenuates Sensorineural Hearing Loss in an Animal Model and Population-Based Cohort Study

    International Journal of Environmental Research and Public Health Article Dextromethorphan Attenuates Sensorineural Hearing Loss in an Animal Model and Population-Based Cohort Study Hsin-Chien Chen 1,* , Chih-Hung Wang 1,2 , Wu-Chien Chien 3,4 , Chi-Hsiang Chung 3,4, Cheng-Ping Shih 1, Yi-Chun Lin 1,2, I-Hsun Li 5,6, Yuan-Yung Lin 1,2 and Chao-Yin Kuo 1 1 Department of Otolaryngology-Head and Neck Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan; [email protected] (C.-H.W.); [email protected] (C.-P.S.); [email protected] (Y.-C.L.); [email protected] (Y.-Y.L.); [email protected] (C.-Y.K.) 2 Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan 3 School of Public Health, National Defense Medical Center, Taipei 114, Taiwan; [email protected] (W.-C.C.); [email protected] (C.-H.C.) 4 Department of Medical Research, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan 5 Department of Pharmacy Practice, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan; [email protected] 6 School of Pharmacy, National Defense Medical Center, Taipei 114, Taiwan * Correspondence: [email protected]; Tel.: +886-2-8792-7192; Fax: +886-2-8792-7193 Received: 31 July 2020; Accepted: 28 August 2020; Published: 31 August 2020 Abstract: The effect of dextromethorphan (DXM) use in sensorineural hearing loss (SNHL) has not been fully examined. We conducted an animal model and nationwide retrospective matched-cohort study to explore the association between DXM use and SNHL.
  • A Guide to Glutamate Receptors

    A Guide to Glutamate Receptors

    A guide to glutamate receptors 1 Contents Glutamate receptors . 4 Ionotropic glutamate receptors . 4 - Structure ........................................................................................................... 4 - Function ............................................................................................................ 5 - AMPA receptors ................................................................................................. 6 - NMDA receptors ................................................................................................. 6 - Kainate receptors ............................................................................................... 6 Metabotropic glutamate receptors . 8 - Structure ........................................................................................................... 8 - Function ............................................................................................................ 9 - Group I: mGlu1 and mGlu5. .9 - Group II: mGlu2 and mGlu3 ................................................................................. 10 - Group III: mGlu4, mGlu6, mGlu7 and mGlu8 ............................................................ 10 Protocols and webinars . 11 - Protocols ......................................................................................................... 11 - Webinars ......................................................................................................... 12 References and further reading . 13 Excitatory synapse pathway
  • S Efficacy in Treating Bipolar Depression: a Longitudinal Proton Magnetic Resonance Spectroscopy Study

    S Efficacy in Treating Bipolar Depression: a Longitudinal Proton Magnetic Resonance Spectroscopy Study

    Neuropsychopharmacology (2009) 34, 1810–1818 & 2009 Nature Publishing Group All rights reserved 0893-133X/09 $32.00 www.neuropsychopharmacology.org Decreased Glutamate/Glutamine Levels May Mediate Cytidine’s Efficacy in Treating Bipolar Depression: A Longitudinal Proton Magnetic Resonance Spectroscopy Study Sujung J Yoon*,1, In Kyoon Lyoo2,3, Charlotte Haws4,5, Tae-Suk Kim1, Bruce M Cohen2,6 and 4,5 Perry F Renshaw 1Department of Psychiatry, Catholic University College of Medicine, Seoul, South Korea; 2Department of Psychiatry, Harvard Medical School, Boston, MA, USA; 3Brain Imaging Center and Clinical Research Center, Seoul National University Hospital, Seoul, South Korea; 4Department of 5 Psychiatry, The Brain Institute, University of Utah, Salt Lake City, UT, USA; Department of Veterans Affairs VISN 19 MIRECC, Salt Lake City, UT, 6 USA; Molecular Pharmacology Laboratory, Harvard Medical School, McLean Hospital, Belmont, MA, USA Targeting the glutamatergic system has been suggested as a promising new option for developing treatment strategies for bipolar depression. Cytidine, a pyrimidine, may exert therapeutic effects through a pathway that leads to altered neuronal-glial glutamate cycling. Pyrimidines are also known to exert beneficial effects on cerebral phospholipid metabolism, catecholamine synthesis, and mitochondrial function, which have each been linked to the pathophysiology of bipolar depression. This study was aimed at determining cytidine’s efficacy in bipolar depression and at assessing the longitudinal effects of cytidine on cerebral glutamate/glutamine levels. Thirty-five patients with bipolar depression were randomly assigned to receive the mood-stabilizing drug valproate plus either cytidine or placebo for 12 weeks. Midfrontal cerebral glutamate/glutamine levels were measured using proton magnetic resonance spectroscopy before and after 2, 4, and 12 weeks of oral cytidine administration.
  • Galantamine Potentiates the Neuroprotective Effect of Memantine Against NMDA-Induced Excitotoxicity Joao~ P

    Galantamine Potentiates the Neuroprotective Effect of Memantine Against NMDA-Induced Excitotoxicity Joao~ P

    Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity Joao~ P. Lopes1, Glauco Tarozzo1, Angelo Reggiani1, Daniele Piomelli1,2 & Andrea Cavalli1,3 1D3 – Drug Discovery and Development Department, Istituto Italiano di Tecnologia, Via Morego, 16163, Genova, Italy 2Departments of Anatomy and Neurobiology and Biological Chemistry, University of California, Irvine, CA, 92697-4621 3Department of Pharmacy and Biotechnologies, Alma Mater Studiorum, Bologna University, Via Belmeloro, 40126, Bologna, Italy Keywords Abstract Alzheimer’s disease, drug combination, N NMDA neurotoxicity, NR2B, The combination of memantine, an -methyl-D-aspartate (NMDA) receptor polypharmacology, primary cortical neurons antagonist, with an acetylcholinesterase inhibitor (AChEI) is the current stan- dard of care in Alzheimer’s disease (AD). Galantamine, an AChEI currently Correspondence marketed for the treatment of AD, exerts memory-enhancing and neuroprotec- Andrea Cavalli, D3 – Drug Discovery and tive effects via activation of nicotinic acetylcholine receptors (nAChRs). Here, Development Department, Istituto Italiano we investigated the neuroprotective properties of galantamine in primary cul- di Tecnologia – Via Morego, 30, 16163 tures of rat cortical neurons when given alone or in combination with meman- Genova, Italy. Tel: +39 010 71781530; Fax: +39 010 tine. In agreement with previous findings, we found that memantine was fully 71781228; E-mail: [email protected] effective in reversing NMDA toxicity at concentrations of 2.5 and 5 lmol/L. Galantamine also completely reversed NMDA toxicity at a concentration of Funding Information 5 lmol/L. The a7 and a4b2 nAChR antagonists, methyllycaconitine, and dihy- No funding information provided. dro-b-erythroidine blocked the neuroprotective effect of galantamine, demon- strating the involvement of nAChRs.
  • Exploring the Activity of an Inhibitory Neurosteroid at GABAA Receptors

    Exploring the Activity of an Inhibitory Neurosteroid at GABAA Receptors

    1 Exploring the activity of an inhibitory neurosteroid at GABAA receptors Sandra Seljeset A thesis submitted to University College London for the Degree of Doctor of Philosophy November 2016 Department of Neuroscience, Physiology and Pharmacology University College London Gower Street WC1E 6BT 2 Declaration I, Sandra Seljeset, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I can confirm that this has been indicated in the thesis. 3 Abstract The GABAA receptor is the main mediator of inhibitory neurotransmission in the central nervous system. Its activity is regulated by various endogenous molecules that act either by directly modulating the receptor or by affecting the presynaptic release of GABA. Neurosteroids are an important class of endogenous modulators, and can either potentiate or inhibit GABAA receptor function. Whereas the binding site and physiological roles of the potentiating neurosteroids are well characterised, less is known about the role of inhibitory neurosteroids in modulating GABAA receptors. Using hippocampal cultures and recombinant GABAA receptors expressed in HEK cells, the binding and functional profile of the inhibitory neurosteroid pregnenolone sulphate (PS) were studied using whole-cell patch-clamp recordings. In HEK cells, PS inhibited steady-state GABA currents more than peak currents. Receptor subtype selectivity was minimal, except that the ρ1 receptor was largely insensitive. PS showed state-dependence but little voltage-sensitivity and did not compete with the open-channel blocker picrotoxinin for binding, suggesting that the channel pore is an unlikely binding site. By using ρ1-α1/β2/γ2L receptor chimeras and point mutations, the binding site for PS was probed.
  • Prevention Or Amelioration of Autism-Like Symptoms in Animal Models: Will It Bring Us Closer to Treating Human ASD?

    Prevention Or Amelioration of Autism-Like Symptoms in Animal Models: Will It Bring Us Closer to Treating Human ASD?

    International Journal of Molecular Sciences Review Prevention or Amelioration of Autism-Like Symptoms in Animal Models: Will it Bring Us Closer to Treating Human ASD? Asher Ornoy 1,* , Liza Weinstein-Fudim 1 and Zivanit Ergaz 1,2 1 Laboratory of Teratology, Department of Medical Neurobiology, Hebrew University Hadassah Medical School, Jerusalem 9112001, Israel; [email protected] 2 Neonatology Department, Hadassah Hebrew University Medical Center, Jerusalem 9112001, Israel; [email protected] * Correspondence: [email protected]; Tel.: +972-2-6758329 Received: 17 February 2019; Accepted: 23 February 2019; Published: 1 March 2019 Abstract: Since the first animal model of valproic acid (VPA) induced autistic-like behavior, many genetic and non-genetic experimental animal models for Autism Spectrum Disorder (ASD) have been described. The more common non-genetic animal models induce ASD in rats and mice by infection/inflammation or the prenatal or early postnatal administration of VPA. Through the establishment of these models, attempts have been made to ameliorate or even prevent ASD-like symptoms. Some of the genetic models have been successfully treated by genetic manipulations or the manipulation of neurotransmission. Different antioxidants have been used (i.e., astaxanthin, green tea, piperine) to reduce brain oxidative stress in VPA-induced ASD models. Agents affecting brain neurotransmitters (donepezil, agmatine, agomelatine, memantine, oxytocin) also successfully reduced ASD-like symptoms. However, complete prevention of the development of symptoms was achieved only rarely. In our recent study, we treated mouse offspring exposed on postnatal day four to VPA with S-adenosine methionine (SAM) for three days, and prevented ASD-like behavior, brain oxidative stress, and the changes in gene expression induced by VPA.
  • The Effects of Dextromethorphan on Response Acquisition with Delayed Reinforcement

    The Effects of Dextromethorphan on Response Acquisition with Delayed Reinforcement

    Western Michigan University ScholarWorks at WMU Dissertations Graduate College 6-2005 The Effects of Dextromethorphan on Response Acquisition with Delayed Reinforcement Thomas B. Morgan Western Michigan University Follow this and additional works at: https://scholarworks.wmich.edu/dissertations Part of the Mental and Social Health Commons, and the Psychology Commons Recommended Citation Morgan, Thomas B., "The Effects of Dextromethorphan on Response Acquisition with Delayed Reinforcement" (2005). Dissertations. 1050. https://scholarworks.wmich.edu/dissertations/1050 This Dissertation-Open Access is brought to you for free and open access by the Graduate College at ScholarWorks at WMU. It has been accepted for inclusion in Dissertations by an authorized administrator of ScholarWorks at WMU. For more information, please contact [email protected]. THE EFFECTS OF DEXTROMETHORPHAN ON RESPONSE ACQUISITION WITH DELAYED REINFORCEMENT by Thomas B. Morgan A Dissertation Submitted to the Faculty of The Graduate College in partial fulfillment of the requirements for the Degree of Doctor of Philosophy Department of Psychology Western Michigan University Kalamazoo, Michigan June 2005 THE EFFECTS OF DEXTROMETHORPHAN ON RESPONSE ACQUISITION WITH DELAYED REINFORCEMENT Thomas B. Morgan, Ph. D. Western Michigan University, 2005 The current study examined in 2-h sessions the effects of intraperitoneal injec- tions of dextromethorphan (DM) (0.0, 40.0, 60.0, and 80.0 mg/kg) on the acquisition of lever-press responding in rats that were exposed to a two-lever procedure in which responses on the reinforcement lever (RL) were reinforced with food after a 15-s re- setting delay and responses on the cancellation lever cancelled a scheduled reinforcer.
  • A Steroid Modulatory Domain on NR2B Controls N-Methyl-D-Aspartate Receptor Proton Sensitivity

    A Steroid Modulatory Domain on NR2B Controls N-Methyl-D-Aspartate Receptor Proton Sensitivity

    A steroid modulatory domain on NR2B controls N-methyl-D-aspartate receptor proton sensitivity Ming-Kuei Jang†, Dale F. Mierke‡, Shelley J. Russek†, and David H. Farb†§ †Laboratory of Molecular Neurobiology, Department of Pharmacology, Boston University School of Medicine, 715 Albany Street, Boston, MA 02118; and ‡Department of Molecular Pharmacology, Division of Biology and Medicine, and Department of Chemistry, Brown University, Providence, RI 02912 Edited by Erminio Costa, University of Illinois, Chicago, IL, and approved April 5, 2004 (received for review March 15, 2004) N-methyl-D-aspartate (NMDA) receptor function is modulated by have been shown to regulate native NMDA receptors via distinct several endogenous molecules, including zinc, polyamines, pro- recognition sites; PS modulation is also not dependent on the tons, and sulfated neurosteroids. Zinc, polyamines, and phenyleth- redox state of the receptor (24). To define the mode of action of anolamines exert their respective modulatory effects by exacer- PS and to determine structural components at the NMDA bating or relieving tonic proton inhibition. Here, we report that receptor that are critical for PS modulation, we took advantage pregnenolone sulfate (PS) uses a unique mechanism for enhance- of our previous finding that PS differentially modulates activity ment of NMDA receptor function that is independent of the proton of recombinant receptors containing different NR2 subunits sensor. We identify a steroid modulatory domain, SMD1, on the (25). PS potentiates the response of recombinant NMDA re- NMDA receptor NR2B subunit that is critical for both PS enhance- ceptors containing NR2A or NR2B subunits, while inhibiting the ment and proton sensitivity. This domain includes the J͞K helices response of receptors containing NR2C or NR2D subunits.
  • NMDA Receptors Containing the Glun2d Subunit Control Neuronal Function in the Subthalamic Nucleus

    NMDA Receptors Containing the Glun2d Subunit Control Neuronal Function in the Subthalamic Nucleus

    The Journal of Neuroscience, December 2, 2015 • 35(48):15971–15983 • 15971 Cellular/Molecular NMDA Receptors Containing the GluN2D Subunit Control Neuronal Function in the Subthalamic Nucleus X Sharon A. Swanger,1* Katie M. Vance,1* Jean-Franc¸ois Pare,3 Florence Sotty,4 Karina Fog,4 Yoland Smith,2,3 and X Stephen F. Traynelis1 1Department of Pharmacology and 2Department of Neurology, Emory University School of Medicine, Atlanta, Georgia 30322, 3Yerkes National Primate Research Center and Morris K. Udall Center of Excellence for Parkinson’s Disease Research, Emory University, Atlanta, Georgia 30329, and 4H. Lundbeck A/S, Division of Neurodegeneration and Biologics, Ottiliavej 9, DK-2500 Valby, Denmark The GluN2D subunit of the NMDA receptor is prominently expressed in the basal ganglia and associated brainstem nuclei, including the subthalamic nucleus (STN), globus pallidus, striatum, and substantia nigra. However, little is known about how GluN2D-containing NMDA receptors contribute to synaptic activity in these regions. Using Western blotting of STN tissue punches, we demonstrated that GluN2D is expressed in the rat STN throughout development [age postnatal day 7 (P7)–P60] and in the adult (age P120). Immunoelectron microscopy of the adult rat brain showed that GluN2D is predominantly expressed in dendrites, unmyelinated axons, and axon terminals within the STN. Using subunit-selective allosteric modulators of NMDA receptors (TCN-201, ifenprodil, CIQ, and DQP-1105), we provide evidence that receptors containing the GluN2B and GluN2D subunits mediate responses to exogenously applied NMDA and glycine, as well as synaptic NMDA receptor activation in the STN of rat brain slices. EPSCs in the STN were mediated primarily by AMPA and NMDA receptors and GluN2D-containing NMDA receptors controlled the slow deactivation time course of EPSCs in the STN.
  • A Review of Glutamate Receptors I: Current Understanding of Their Biology

    A Review of Glutamate Receptors I: Current Understanding of Their Biology

    J Toxicol Pathol 2008; 21: 25–51 Review A Review of Glutamate Receptors I: Current Understanding of Their Biology Colin G. Rousseaux1 1Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada Abstract: Seventy years ago it was discovered that glutamate is abundant in the brain and that it plays a central role in brain metabolism. However, it took the scientific community a long time to realize that glutamate also acts as a neurotransmitter. Glutamate is an amino acid and brain tissue contains as much as 5 – 15 mM glutamate per kg depending on the region, which is more than of any other amino acid. The main motivation for the ongoing research on glutamate is due to the role of glutamate in the signal transduction in the nervous systems of apparently all complex living organisms, including man. Glutamate is considered to be the major mediator of excitatory signals in the mammalian central nervous system and is involved in most aspects of normal brain function including cognition, memory and learning. In this review, the basic biology of the excitatory amino acids glutamate, glutamate receptors, GABA, and glycine will first be explored. In the second part of this review, the known pathophysiology and pathology will be described. (J Toxicol Pathol 2008; 21: 25–51) Key words: glutamate, glycine, GABA, glutamate receptors, ionotropic, metabotropic, NMDA, AMPA, review Introduction and Overview glycine), peptides (vasopressin, somatostatin, neurotensin, etc.), and monoamines (norepinephrine, dopamine and In the first decades of the 20th century, research into the serotonin) plus acetylcholine. chemical mediation of the “autonomous” (autonomic) Glutamatergic synaptic transmission in the mammalian nervous system (ANS) was an area that received much central nervous system (CNS) was slowly established over a research activity.
  • SULT1E1 Inhibits Cell Proliferation and Invasion by Activating Pparγ in Breast Cancer

    SULT1E1 Inhibits Cell Proliferation and Invasion by Activating Pparγ in Breast Cancer

    Journal of Cancer 2018, Vol. 9 1078 Ivyspring International Publisher Journal of Cancer 2018; 9(6): 1078-1087. doi: 10.7150/jca.23596 Research Paper SULT1E1 inhibits cell proliferation and invasion by activating PPARγ in breast cancer Yali Xu1, Xiaoyan Lin1, Jiawen Xu1, Haiyan Jing1, Yejun Qin1, Yintao Li2 1. Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, P.R. China 2. Department of Medical Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, P.R. China Corresponding author: Yejun Qin, Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong University, No. 324 Jingwu Road, Jinan, Shandong, 250021, China. Tel: +86-531-68776430. E-mail: [email protected] and Yintao Li, Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong University, No. 440 Jiefang Road, Jinan, Shandong, 250117, China. Tel: +86-531-87984777. E-mail: [email protected] © Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2017.10.31; Accepted: 2018.01.29; Published: 2018.02.28 Abstract Sulfotransferase family 1E member 1 (SULT1E1) is known to catalyze sulfoconjugation and play a crucial role in the deactivation of estrogen homeostasis, which is involved in tumorigenesis and the progression of breast and endometrial cancers. Our previous study has shown that the protein levels of SULT1E1 were decreased in breast cancer; however, the underlying mechanism is still poorly understood. In this study, we explored the functional and molecular mechanisms by which SULT1E1 influenced breast cancer.
  • GLYX-13 Produces Rapid Antidepressant Responses with Key Synaptic and Behavioral Effects Distinct from Ketamine

    GLYX-13 Produces Rapid Antidepressant Responses with Key Synaptic and Behavioral Effects Distinct from Ketamine

    Neuropsychopharmacology (2017) 42, 1231–1242 © 2017 American College of Neuropsychopharmacology. All rights reserved 0893-133X/17 www.neuropsychopharmacology.org GLYX-13 Produces Rapid Antidepressant Responses with Key Synaptic and Behavioral Effects Distinct from Ketamine 1,5 1,5 1,2 1 1 1 Rong-Jian Liu , Catharine Duman , Taro Kato , Brendan Hare , Dora Lopresto , Eunyoung Bang , 3 3,4 1 1 *,1 Jeffery Burgdorf , Joseph Moskal , Jane Taylor , George Aghajanian and Ronald S Duman 1Departments of Psychiatry and Neurosciences, Yale University School of Medicine, New Haven, CT, USA; 2Sumitomo Dainippon Pharma Co, Suita, 3 Osaka, Japan; Falk Center for Molecular Therapeutics, Department of Biomedical Engineering, Northwestern University, Evanston IL, USA; 4 Naurex, Inc., Evanston, IL, USA GLYX-13 is a putative NMDA receptor modulator with glycine-site partial agonist properties that produces rapid antidepressant effects, but without the psychotomimetic side effects of ketamine. Studies were conducted to examine the molecular, cellular, and behavioral actions of GLYX-13 to further characterize the mechanisms underlying the antidepressant actions of this agent. The results demonstrate that a single dose of GLYX-13 rapidly activates the mTORC1 pathway in the prefrontal cortex (PFC), and that infusion of the selective mTORC1 inhibitor rapamycin into the medial PFC (mPFC) blocks the antidepressant behavioral actions of GLYX-13, indicating a requirement for mTORC1 similar to ketamine. The results also demonstrate that GLYX-13 rapidly increases the number and function of spine synapses in the apical dendritic tuft of layer V pyramidal neurons in the mPFC. Notably, GLYX-13 significantly increased the synaptic responses to hypocretin, a measure of thalamocortical synapses, compared with its effects on 5-HT responses, a measure of cortical- cortical responses mediated by the 5-HT receptor.